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Objective: To define ‘‘best possible’’ outcomes in total minimally invasive
transthoracic esophagectomy (ttMIE).
Background: TtMIE, performed by experts in patients with low comorbidity,
may serve as a benchmark procedure for esophagectomy.
Patients and Methods: From a cohort of 1057 ttMIE, performed over a
5-year period in 13 high-volume centers for esophageal surgery, we selected a
study group of 334 patients (31.6%) that fulfilled criteria of low comorbidity
(American Society of Anesthesiologists score 2, WHO/ECOG score 1,
age 65 years, body mass index 19–29 kg/m2). Endpoints included postop-
erative morbidity measured by the Clavien-Dindo classification and the
comprehensive complication index. Benchmark values were defined as the
75th percentile of the median outcome parameters of the participating centers
to represent best achievable results.
Results: Benchmark patients were predominantly male (82.9%) with a median
age of 58 years (53–62). High intrathoracic (Ivor Lewis) and cervical esoph-
agogastrostomy (McKeown) were performed in 188 (56.3%) and 146 (43.7%)
patients, respectively. Median (IQR) ICU and hospital stay was 0 (0–2) and 12
(9–18) days, respectively. 56.0% of patients developed at least 1 complication,
and 26.9% experienced major morbidity (grade III), mostly related to
pulmonary complications (25.7%), anastomotic leakage (15.9%), and cardiac
events (13.5%). Benchmark values at 30 days after hospital discharge were
55.7% and 30.8% for overall and major complications, 18.0% for
readmission, 3.1% for positive resection margins, and 23 for lymph node
yield. Benchmarks at 30 and 90 days were0.0%and4.6% for mortality, and
40.8 and 42.8 for the comprehensive complication index, respectively.
Conclusion: This outcome analysis of patients with low comorbidity under-
going ttMIE may serve as a reference to evaluate surgical performance in
major esophageal resection.
Keywords: benchmark values, comprehensive complication index,
minimally invasive esophagectomy, outcome
(Ann Surg 2017;xx:xxx–xxx)
B enchmarking may be defined as a method to find a point ofreference – the benchmark – against which the results of others
can be compared. Usually, a benchmark describes a ‘‘best possible’’
outcome under ideal circumstances. Benchmarking is a standard tool
to assess industrial productivity and efficacy, and represents an
integral part of management concepts such as continuous quality
improvement.1 With the growing need to monitor performance
within healthcare systems, the concept of benchmarking is gaining
considerable weight in the field of surgery, particularly with the aim
to evaluate complex and cost-intensive procedures.2
In this context, we conceived this multicenter analysis of total
minimally invasive transthoracic esophagectomy (ttMIE). Minimal
invasive surgery for esophageal cancerwas introduced around 25 years
ago, with the aim to reduce procedure-related morbidity.3,4 Hybrid
approaches, that combine either laparoscopy with thoracotomy or
thoracoscopy with laparotomy, have become common procedures in
many centers around the world. In contrast, the technically more
complex and even less invasive total (laparoscopic-thoracoscopic)
MIE has been adopted by a minority of esophageal surgeons only.5,6
TtMIE was pioneered by James Luketich, who, in 2012, published an
impressive series of more than 1000 consecutive patients with excel-
lent outcomes.7 As this study depicts a unique and since then unparal-
leled experience of a single dedicated surgeon, it may not adequately
reflect the results of many centers that started total MIE during the
course of recent years. In this regard, our aim was to create a realistic
snapshot of the actual state of this procedure in international expert
centers for esophageal surgery by means of a benchmark analysis.
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Parallel to other recent outcome research on esophageal
cancer surgery,8,9 we implemented the comprehensive complication
index (CCI). The CCI is a novel scoring system that permits to
integrate all complications into a single value on a scale from 0 (no
complication) to 100 (death).10 The fundamentally new aspect of this
parameter is that it takes all types and grades of complications into
account. Consequently, the patient’s own perception of morbidity is
reproduced more adequately.11,12 We are convinced that the CCI is
both clinically relevant and easy to understand and therefore, will be
rapidly accepted within the surgical community.
METHODS
Data Collection
Thirteen surgical departments (Amsterdam, Cologne, Eind-
hoven, Gent, Helsinki, Leuven, Mainz, Milano, Philadelphia, Ports-
mouth, Rotterdam, Stockholm, Zurich) participated in this study.
Hospital inclusion criteria were a caseload of more than 20 esoph-
agectomies per year (minimally-invasive and other procedures), the
availability of a prospective database, and a special commitment to
esophageal surgery as documented by recent publications. Patients
that underwent ttMIE [Ivor Lewis (I.L.) or McKeown (M.K.) pro-
cedures] over a 5-year period (June 1, 2011–May 31, 2016) for
malignant or benign indications were eligible; conversions to open
surgery, hybrid, and transhiatal procedures were excluded. Data were
collected via a secure online platform (https://www.esobenchmar-
k.org/) provided by the University Hospital of Zurich. We used a data
entry management system to meet international standards for online
databases including fully anonymized data. In agreement with each
participating center, no data are reported with patient or hospital
identifiers. The information collected per patient included basic
demographics, American Society of Anesthesiologists (ASA)- and
WHO/ECOG-scores, tumor-specific parameters, technical details of
the surgical procedure, and postoperative complications. Time-end-
points for analysis of postoperative events were at 30 and 90 days
after hospital discharge. The complications basic platform published
by the Esophagectomy Complications Consensus Group (ECCG)13
was used to classify all adverse events, which were then graded
according to the Clavien-Dindo (CD) classification.14 Approval from
the ethical committee of the Canton of Zurich (BASEC-No. 2016–
01430) and from the institutional review boards of each respective
center was obtained before analysis.
Study Cohort and Inclusion Criteria of Low
Comorbidity
The basic dataset included 1057 patients after ttMIE with a
median (IQR) age of 64 (57–70) and a median (IQR) body mass
index (BMI) of 25.6 kg/m2 (22.8–28.4); 80.5% were men. From this
basic dataset, 334 patients (31.6%) with a low risk profile (ECOG
grade1 and ASA score2, age65 years, and BMI 19–29 kg/m2)
were selected to form the study group for benchmark analysis
(Fig. 1). Criteria of low comorbidity were derived from statistical
analysis (Fisher exact test of proportions) of the whole patient cohort.
Age >65 years and BMI >30 kg/m2 were significantly associated
with higher 90-day mortality (P< 0.05). These cutoff parameters are
consistent with the results of a recent publication that identified an
ECOG score >1, age >65 years, and obesity as predictors of major
morbidity after esophagectomy.15
Performance Metrics of Benchmarking
Primary outcome measures for benchmark analysis were
overall and major (CD 3a) morbidity, readmissions, anastomotic,
and pulmonary complications; all at 30 days after hospital discharge.
In addition, positive resection margins, the number of examined
lymph nodes (LN), the 30- and 90-day CCI of patients that developed
at least 1 CD grade II complication, and 30- and 90-day mortality
rates were calculated.
Statistical Analysis
Data are reported as median and IQR for continuous variables
or number and proportions (%) for categorical variables. For sub-
group analyses (ie, comparison of the surgical technique or bench-
mark vs non-benchmark groups), continuous variables were
compared using the Mann-Whitney U test. Categorical variables
were compared using the Fischer exact or the Pearson x2 tests, where
appropriate. Overall survival rates were calculated according to the
Kaplan-Meier function. All P values were 2-sided and considered
statistically significant if P 0.05.
Benchmark values were exclusively derived from the study
cohort with low comorbidity (n ¼ 334). As previously described,2
benchmarks were defined as the 75th percentile of the median
outcome parameters of the participating centers representing best
achievable results. Briefly, to adjust for variability in outcomes
across centers,2 we first calculated the median values of continuous
parameters and the proportions of categorical variables for each
participating center. After calculating the median and IQR of the
center specific values, the 75th percentile was chosen as the bench-
mark value for all outcomes indicated above, with the exception of
the number of lymph nodes examined, where the 25th percentile was
chosen indicating the higher number the better. The reported 30- and
90-day CCI was derived from patients with available data for both 30
as well as 90 days of follow up developing at least 1 CD grade II
complication.2
Statistical analysis was performed using R version 3.3.2 (R
Core Team, GNU GPL v2 License), R Studio version 1.0.44 (RStu-
dio, Inc. GNUAffero General Public License v3, Boston, MA, 2016)
with the graphical user interface (GUI) rBiostatistics.com alpha
version (rBiostatistics.com, Zurich, Canton of Zurich, Switzerland,
2016).
RESULTS
Basic Characteristics of Benchmark Patients
The 334 patients (31.6%) patients comprising the benchmark
group were predominantly male (82.9%) with a median age of
58 years (IQR 53–62) (Table 1). Except for 2 patients, the indication
for esophagectomy was esophageal cancer, with adenocarcinoma
(77.2%) being the most common histological entity. Accordingly,
most tumors were located in the distal esophagus (63.5%) or at the
FIGURE 1. Flowchart depicting the basic dataset, exclusion
criteria, and benchmark cohort.
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esophagogastric junction (30.1%). Furthermore, the majority of
patients received neoadjuvant treatment, either chemotherapy alone
(15.3%) or chemoradiation (62.6%). Seventy-two patients (21.6%)
underwent esophagectomy without neoadjuvant treatment.
Postoperative Outcome in Benchmark Patients
Overall morbidity at 30 days after discharge was 56.0%, with
90 patients (26.9%) experiencing major complications (CD grade
IIIa) (Table 2, Fig. 2). Although some variation was observed,
overall and major morbidity was not statistically different comparing
the different surgical centers (Fig. 2). Thirty- and ninety-day mor-
tality rates were 0.9% and 2.4%, respectively. Most common com-
plications were pulmonary (25.7%; CD grades I, II, IIIA, IIIb, IVa,
IVb, and V in 13, 29, 9, 4, 23, 4, and 4 patients, respectively),
followed by anastomotic leaks (15.9%; CD grades I, II, IIIA, IIIb,
IVa, IVb, and V in 7, 11, 8, 15, 9, 2, and 1 patients, respectively), and
cardiac events (13.5%; CD grades I, II, IIIA, IIIb, IVa, IVb, and V in
6, 30, 1, 1, 4, 0, and 3 patients, respectively). Fatal outcomes (CD
grade V, n ¼ 8) were highly associated with anastomotic leakage (6
patients); only 1 patient suffered a cardiac arrest without any other
documented complication. The median CCI was 8.7 (IQR 0.0–30.8)
including morbidity leading to readmission. Median intensive care
unit (ICU) stay was 0 days (IQR 0–2) and median hospital stay was
12 days (IQR 9–18). Forty-eight patients (14.4%) with complicated
postoperative course needed higher level of care with readmission to
ICU. Blood transfusions were administered intraoperatively in 2
patients (0.6%) and postoperatively in 25 patients (7.5%). Twenty-
four patients (7.2%) required rehospitalization within 30 days of
discharge. Readmission was most commonly related to delayed
gastric emptying (3 patients), anastomotic stricture (3 patients),
and overeating or dumping syndrome (9 patients). Three patients
were readmitted with late anastomotic leaks, 1 of whom developed a
gastro-tracheal fistula. Another readmission was due to an abscess
adjacent to the pancreas. The majority of cases were treated conser-
vatively (eg, antibiotics, drainage, nil per mouth) or endoscopically
(pyloric dilation, stent placement, tracheostomy). One patient un-
derwent redo-surgery for a positive resection margin and was recon-
structed with colon interposition.
Intrathoracic and Cervical Anastomosis
In the benchmark group, high intrathoracic (IL procedure) and
cervical esophagogastrostomy (MK procedure) were performed in
TABLE 1. Patient Characteristics
All Patients
n ¼ 1057 (100%)
Non-benchmark patients
n ¼ 723 (68.4%)
Benchmark patients
n ¼ 334 (31.6%) P
Age yrs (median, IQR) 64 (57–70) 67 (61–72) 58 (53–62) <0.01
BMI kg/m2 (median, IQR) 25.6 (22.8–28.4) 25.8 (22.6–29.7) 25.3 (23.3–27.5) <0.01
Male, n (%) 851 (79.4) 574 (79.4) 277 (82.9) ns
WHO/ECOG performance status, n (%)
Grade 0 630 (59.6) 407 (56.3) 223 (66.8) <0.01
Grade I 387 (36.6) 276 (38.2) 111 (33.2) –
Grade II 40 (3.8) 40 (5.5) – –
ASA status, n (%)
Grade I 226 (21.4) 118 (16.3) 108 (32.3) <0.01
Grade II 539 (51) 313 (43.3) 226 (67.7) –
Grade III 288 (27.2) 288 (39.8) – –
Grade IV 4 (0.4) 4 (0.6) – –
Histology, n (%)
AC 813 (76.9) 555 (76.8) 258 (77.2) ns
SCC 224 (21.2) 155 (21.4) 69 (20.7) –
Other type of malignancy 13 (1.2) 8 (1.1) 5 (1.5) –
Benign 7 (0.7) 5 (0.7) 2 (0.6) –
Tumor location, n (%)
Proximal half of esophagus 47 (4.4) 26 (3.6) 21 (6.3) ns
Distal half of esophagus 655 (62) 443 (61.3) 212 (63.5) –
Esophagogastric junction 355 (33.6) 254 (35.1) 101 (30.2) –
Preoperative therapy, n (%)
None 291 (27.5) 219 (30.3) 72 (21.6) 0.02
Chemotherapy 125 (11.9) 74 (10.2) 51 (15.3) –
Radiotherapy 4 (0.4) 3 (0.4) 1 (0.3) –
Radiochemotherapy 635 (60.1) 426 (58.9) 209 (62.6) –
Definitive radiohemotherapy 2 (0.2) 1 (0.1) 1 (0.3) –
Surgical approach
McKeown 482 (45.6) 336 (46.5) 146 (43.7) ns
Ivor Lewis 575 (54.4) 387 (53.5) 188 (56.3) –
UICC Stages, n (%)
IA 395 (37.5) 279 (38.8) 116 (34.7) ns
IB 103 (9.8) 71 (9.9) 32 (9.6) –
IIA 150 (14.3) 101 (14) 49 (14.7) –
IIB 96 (9.1) 64 (8.9) 32 (9.6) –
IIIA 151 (14.4) 99 (13.8) 52 (15.6) –
IIIB 76 (7.2) 47 (6.5) 29 (8.7) –
IIIC 67 (6.4) 51 (7.1) 16 (4.8) –
IV 14 (1.3) 8 (1.1) 6 (1.8) –
ECOG indicates Eastern Cooperative Oncology Group; IQR, interquartile range; ns, not significant; UICC, Union internationale contre le cancer TNM classification for esophageal
cancer 7
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188 (56.3%) and 146 (43.7%) patients, respectively. Basic patient
characteristics, WHO/ECOG status, and UICC stages were similar,
but ASA grades were significantly higher in MK patients. Also,
squamous cell carcinoma and proximal esophageal localization of
the tumor were significantly more common in MK patients. No
statistically significant differences were found for overall (52.7% and
60.3%) and major (28.2% and 25.3%) morbidity, the median CCI
[8.7 (IQR 0–26.2) and 20.9 (IQR 0–33.7)], anastomotic leakage
rates (14.9% and 17.1%), pulmonary (25.5% and 26.0%), and cardiac
complications (11.2% and 16.4%) in both groups, respectively.
Likewise, positive resection margins (2.2% and 4.2%), hospital
readmission rates (6.6% and 5.7%), and 30- (0.5% and 1.4%) and
TABLE 2. Postoperative Outcomes
All Patients
n ¼ 1057 (100%)
Non-benchmark Patients
n ¼ 723 (68.4%)
Benchmark Patients
n ¼ 334 (31.6%) P
LN examined, median (IQR) 25 (18–33) 24 (17–32) 27 (20–34) <0.01
Pos. resection margins, n (%) 35 (3.4) 25 (3.5) 10 (3.0) ns
Complications, n (%)
Any type 629 (59.5) 442 (61.1) 187 (56) 0.04
Minor (CDC Grade I–II) 288 (27.2) 191 (26.4) 97 (29) –
Major (CDC Grade IIIa–V) 341 (32.3) 251 (34.7) 90 (26.9) 0.01
Anastomotic leak 170 (16.1) 117 (16.2) 53 (15.9) ns
Conduit necrosis 21 (2) 16 (2.2) 5 (1.5) ns
Chyle leak 58 (5.5) 43 (5.9) 15 (4.5) ns
Gastrointestinal event 85 (8) 53 (7.3) 32 (9.6) ns
Pulmonary event 328 (31) 242 (33.5) 86 (25.7) 0.01
Cardiac event 199 (18.8) 154 (21.3) 45 (13.5) <0.01
Thrombembolic event 27 (2.6) 18 (2.5) 9 (2.7) ns
Urologic event 34 (3.2) 29 (4) 5 (1.5) 0.04
Infection 162 (15.3) 115 (15.9) 47 (14.1) ns
Neurologic event 72 (6.8) 57 (7.9) 15 (4.5) 0.04
Wound infection 28 (2.6) 22 (3) 6 (1.8) ns
Change in level of care, n (%) 162 (15.4) 114 (15.8) 48 (14.4) ns
Blood product utilization, n (%)
Intraoperative 9 (1) 7 (1.1) 2 (0.6) ns
Postoperative 91 (9.8) 66 (10.2) 25 (7.5) –
Intra- and postoperative 7 (0.8) 7 (1.1) –
ICU stay, median (IQR) 1 (2–5.25) 2 (1–6) 2 (1–5.25) <0.01
Hospital stay, median (IQR) 13 (10–21) 13 (10–22) 13 (10–21) ns
Readmission rate within 30 days of discharge, n (%)
Related to esophagectomy 69 (6.7) 49 (7) 20 (6) ns
Unrelated to esophagectomy 9 (0.9) 5 (0.7) 4 (1.2) –
CCI, median (IQR)
30-day 20.9 (0–33.7) 20.9 (0–36.2) 8.7 (0–30.8) 0.01
90-day 20.9 (0–39.2) 26 (0–40) 20.9 (0–34) <0.01
Mortality, n (%)
30-day 22 (2.1) 19 (2.6) 3 (0.9) ns
90-day 55 (5.2) 47 (6.5) 8 (2.4) <0.01
CCI indicates comprehensive complication index; CDC, Clavien-Dindo Classification; IQR, interquartile range, –, Pearson chi-square; LN, lymph node, ns, not significant.
FIGURE 2. Overall (black columns) and
major (CD III, grey columns) complica-
tion rates at 30 days after discharge in
benchmark patients (n ¼ 334) of all 13
surgical centers included.
Schmidt et al Annals of Surgery  Volume XX, Number XX, Month 2017
4 | www.annalsofsurgery.com  2017 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2017 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
CE: S.S.; ANNSURG-D-17-00377; Total nos of Pages: 8;
ANNSURG-D-17-00377
90-day (1.6% and 3.4%) mortality were comparable. In contrast, a
shorter postoperative ICU stay [1 (IQR 0–4) and 1 (IQR 1–4)] (P ¼
0.05) and a lower yield of harvested lymph nodes [26 (IQR 19–33)
and 29 (IQR 22–35)] (P ¼ 0.02) was documented in IL patients.
Benchmark- and Non-benchmark Patients
Benchmark- and non-benchmark cohorts were significantly
different for most basic patient characteristics (ASA score, WHO/
ECOG score, BMI, age). In contrast, both groups were similar
regarding oncological parameters (type of histology, tumor location,
UICC stage) and the type of surgical intervention performed
(Table 1). Considering postoperative outcome, overall and major
morbidity was significantly higher in the non-benchmark cohort.
This was caused by a significantly higher rate of pulmonary, cardiac,
urological, and neurological complications, which also translated
into a higher CCI (P¼ 0.01) and an almost 3-fold increase in 30- and
90-day mortality. In contrast, surgical complications (anastomotic
leakage rate, conduit necrosis, lymphatic leak), and also readmission
rates were similar in both groups (Table 2).
Oncological Outcome in Benchmark- and Non-
benchmark Patients
Oncological results were calculated for patients with either
squamous cell- or adenocarcinoma (AC) only (n ¼ 1037); benign
diseases and other malignancies (n¼ 20) were excluded. Median LN
yield in the whole population of ttMIE patients was 25 (IQR 18–33).
The number of harvested LN was significantly higher in the bench-
mark cohort compared with non-benchmark patients (Table 2). In
contrast, positive resection margins (overall 3.4%) were similar in
benchmark- and non-benchmark patients (Table 2). Overall survival
(OAS) of the whole cohort, and of benchmark- and non-benchmark
patients was 82.3% and 85.5%, 80.8% (1 year), 60.1%, 62.2%, and
58.2% (3 years), and 54.5%, 59.7%, and 52.0% (5
years), respectively.
Benchmark Values ()
Thirty-day benchmark values were based on 326 patients
(97.6%) from 11 centers (2 centers with <10 patients excluded),
and 90-day benchmarks were derived from 218 patients (65.3%)
from 10 centers (2 centers with <10 patients and 1 center with
incomplete 90-day morbidity data reporting excluded) (Table 3).
Benchmark cutoff values 30 days after discharge were
55.7% and 30.8% for overall and major (CD grade III) mor-
bidity,20.0% and31.6% for anastomotic leakage and pulmonary
complications, 3.1% and 23 for positive resection margins and
LN yield, and18.0% for hospital readmission rate. Benchmarks for
the CCI at 30 and 90 days were 40.8 and 42.8 in patients, and
0.0% and 4.6% for 30- and 90-day mortality, respectively.
DISCUSSION
In recent years, outcome assessment has become an important
part of surgical patient care in many developed countries. Hospitals,
departments, and even individual surgeons are increasingly obliged
to measure the quality they deliver and to make this data available to
the public. This information is then often used to rank performance
among competitors with the goal to achieve better transparency and
improved patient autonomy.16 Consequently, Medicare and private
payors, policymakers, the media, physicians, and also patients
increasingly tend to guide their decisions based on such datasets,
a mechanism that strongly impacts on the economic interests of
healthcare providers. Indeed, quality assessment of patient care has
become a powerful public relation tool of the healthcare industry.
On the other hand, there are concerns that the evidence
provided by large national databases, audits, and meta-analyses
may be biased by the heterogeneity of target populations and
procedures performed.17,18 Often, the spectrum of inclusion criteria
is kept rather large to increase sample sizes and no risk adjustment of
cases is performed. For example, a profiling algorithm may ascribe a
superior performance rank to surgeon A due to an inferior mortality
rate compared with surgeon B. However, if the scheme does not
consider the case-mix of patients, this ranking system will be wrong
and cause misunderstanding. Moreover, this may lead to risk-aver-
sion, as healthcare providers may adopt avoidance strategies for
highly morbid or complex cases.19 Other potential weaknesses of
traditional databases are the absence of uniform datasets, the nonex-
istence of consistent validation methods, and the focus on single
outcome parameters only, like ‘‘30-day mortality.’’2
Our present study may overcome these drawbacks as it
provides benchmarks for several clinically relevant endpoints, ready
to be implemented by third-party institutions. Our study complies
with the proposal for standardized reporting of benchmarking as
suggested in a previous study on major hepatectomy,2 with the
exception that we were able to include expert centers from only 2
(instead of 3) continents. A particular strength of our work is that data
were derived from a highly-selected ‘‘optimal’’ group of patients
with low comorbidity that underwent a clearly defined, minimally-
invasive surgical procedure in expert institutions only. This unique
approach allows for the first time to define benchmark parameters, or
‘‘best achievable results’’ for ttMIE. Benchmarking is a novel
concept for the evaluation of surgical procedures and, to our best
knowledge, has not been performed in esophageal surgery cohorts
before. In this context, an interesting novel application of the
benchmark concept may be to directly compare morbidity – and
consequently – its related cost among different types of major
surgery. Thus, the 30-day benchmark values for overall and major
complications in our ttMIE cohort (55.7% and 30.8%, respec-
tively) are considerably higher than those reported after major
hepatectomy2 (26.9% and 6.0%, respectively), but substantially
lower compared with those found in patients undergoing liver
transplantation (80.0% and 42.0%, respectively) (unpublished
data). This further illustrates the potential of benchmarking to
provide elaborate points of reference for use in studies comparing
the impact of morbidity – even across different surgical specialties.
We chose ttMIE as benchmark procedure, because it is one of
the least invasive surgical approaches for esophageal cancer, but
permits a strictly curative approach including systematic
lymphadenectomy in both the thoracic and the abdominal body
cavity. Accordingly, there is increasing evidence that this operation
results in equivalent oncological outcome20 and less postoperative
TABLE 3. Benchmark Results
Benchmark Parameters Benchmark Values
Complications of any severity 55.7%
Major complications (CD Grade IIIa) 30.8%
Anastomotic leak 20%
Pulmonary complication 31.6%
Lymph nodes examined 23¥
Positive resection margins 3.1%
Hospital readmission 18.0%
30-day CCI 40.8
90-day CCI 42.8
30-day mortality 0%
90-day mortality 4.6%
Benchmark values are the 75th percentile of the median proportions, except
¥
is the
25th percentile of the median proportion indicating the high number of lymph nodes
yielded the better.
Annals of Surgery  Volume XX, Number XX, Month 2017 Defining Benchmarks for Transthoracic Esophagectomy
 2017 Wolters Kluwer Health, Inc. All rights reserved. www.annalsofsurgery.com | 5
Copyright © 2017 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
CE: S.S.; ANNSURG-D-17-00377; Total nos of Pages: 8;
ANNSURG-D-17-00377
complications compared with the conventional open approach.21,22
Other techniques, although equally labeled ‘‘minimally invasive’’ –
such as laparoscopically or thoracoscopically assisted, hybrid or
transhiatal esophagectomy – were strictly excluded from this analy-
sis to keep our cohort as homogeneous as possible.
Furthermore, we restricted this data collection to recognized
experts in the field of esophageal surgery. Only centers with a case
load of more than 20 esophagectomies per year, maintaining a
prospective database, and with a documented special interest in
esophageal surgery were included. Also, we insisted on careful
retrospective review of patient files by our coinvestigators in the
event of incompletely submitted case report forms. This stringent
policy resulted in a remarkably high quality of the final dataset with
no missing parameters for primary endpoints at 30 days after
discharge. In order to further enhance the quality of our database,
postoperative complications were assessed according to the system-
atic classification and definitions published by the ECCG.13 This
strategy translated into a high plausibility of our data: key indicators
such as leakage rate and 30- or 90-day mortality are well within the
range of other data collections.23–26
Patient survival in this dataset was superior to that reported by
others for open26 and minimally invasive esophageal cancer sur-
gery.7,23 One the one hand, this relatively high OAS in our series
reflects a technically adequate oncological resection. On the other, it
can be explained by a large proportion of UICC stage 1a carcinoma
(37.5%) in our cohort, which in turn may be caused by the high rate
(72.5%) of induction therapy – in particular radiochemotherapy – a
treatment leading to downstaging in a relevant proportion of patients.
Also, an effect of patient selection cannot be excluded, as some
centers may have not performed ttMIE in advanced carcinoma when
starting their program.
Undeniably, there are some limitations to our study. First, we
found substantial variability in the number of cases submitted per
center. Indeed, 5 centers included more than 100 cases, and 8 centers
less than 50 cases. Although we believe that this diversity should
rather be regarded as a strength than a weakness and might better
reflect reality than a single high-volume experience, it may also
mirror a different degree of experience with this specific procedure
and suggests that learning curve related morbidity may play a role in
our dataset. However, statistical analysis did not reveal higher
morbidity in institutions with less than 50 cases included. In particu-
lar, there was no significant difference for surgical complications
such as anastomotic and conduit leakage. The ‘‘smaller’’ centers,
although still working on their learning curve for ttMIE, invariably
had vast experience in open and hybrid esophagectomy and compli-
cation management, which may explain the similar outcomes com-
pared with the ‘‘larger’’ contributors.
We were not able to perform an intention to treat analysis,
because the conversion rate to open or hybrid access surgery was not
included in our database – this may be considered as a weakness of
the study design. However, our work was strictly focused on post-
operative morbidity of completed ttMIE, and therefore, conversions,
open, and hybrid approaches were strictly excluded.
In our dataset, the anastomotic leakage rate was 15.9%, which
is in the upper range compared with other outcome research.20 On the
one hand, we may attribute this to the strict adoption of the
definitions for this specific complication as published by the
ECCG.13 In contrast to other studies,7 even minor and clinically
unapparent events were recorded and taken into account. On the
other hand, it should be noted that some of the larger (>50 cases)
centers changed their standard technique from MK to IL ttMIE
during the study period, and learning curve-associated effects during
the transition phase cannot be excluded. This might also explain the
lack of correlation between a center’s ttMIE experience level and the
leakage rate. Therefore, at the present stage, it cannot be excluded
that the relatively high leakage rate may be related to the total
minimally invasive approach itself. Nevertheless, the low 30- and 90-
day mortality rates in our benchmark cohort (0.9% and 2.4%,
respectively) reflect a remarkable quality of postoperative care
and consequent management in case of complications. In fact, only
6 deaths (1.8%) in the study group were actually associated with
anastomotic leaks.
Another limitation of our paper is that we cannot exclude that
some adverse events may have been misclassified or even not
documented at all. In particular, CD grade 1 complications were
not equally distributed between centers. From earlier research, we
know that minor morbidity, such as urinary tract infections or
nonstandard lab results, is frequently underreported.2 However,
CD grade 1 complications only have an insignificant impact on
the CCI, and therefore, are not expected to bias the message of
the paper.
In summary, our study is the first to present benchmark values
for outcome parameters after major esophageal surgery. Our database
was derived from a large cohort of patients that exclusively under-
went ttMIE performed by an international group of experts for
esophageal surgery. By restricting our analysis to a subgroup of
‘‘ideal’’ patients with low comorbidity, ‘‘best possible’’ results for
ttMIE were obtained. However, we should keep in mind that our
results represent a snapshot of the actual situation – benchmark
values will presumably improve with time. TtMIE is a very complex
and new procedure with a steep learning curve. With growing
experience, morbidity might shift and this benchmark analysis will
need an update.
Nevertheless, we are confident that our results may soon be
implemented as a reference for other institutions or surgical proce-
dures owing to the novelty of the benchmark concept, the up-to-
dateness of ttMIE, and the lack of comparable outcome values in the
current literature.
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DISCUSSANTS
Antonio J. Torres (Madrid, Spain):
In my opinion, this paper is dealing with a very important
matter at present time. It tries to identify the best possible outcomes
in minimally invasive surgery for esophageal cancer. We can discuss
about the inclusion criteria for considering the low comorbidity
group (specially the age: <65). Also, BMI <30 and benign cases
could be controversial. It would be important to have more informa-
tion about the decision process for selecting the Ivor-Lewis (56.3%)
or the McKeown (43.7%) surgical approach in the benchmark group,
taking into account that 93.7% of the tumors were located at the distal
part of esophagus (63.5%) or at the esophago-gastric junction
(30.2%). The same issue happens in the non-benchmark group, with
similar numbers. It also would be interesting to know if there is any
relationship between the transthoracoscopic anastomosis and the
postoperative fistula.
So, my questions are: First, why to include the 20 non-
malignant cases in this bench marking study? Is it not adding any
bias? Second, if the McKeown’s approach is most frequently per-
formed in squamous cell carcinoma and/or esophageal cancers
located proximally, why Ivor Lewis’s technique was performed only
in 56.3% of the patients? Third, do you consider that performed a
thoracoscopic anastomosis can influence the high rate of anastomotic
leak? Finally, do you have any information about the conversion rate
from laparoscopic and/or thoracoscopic approach to open?
Response from Christian A. Gutschow (Zurich,
Switzerland):
Professor Torres, thank you very much for your questions. You
first asked why we also included non-malignant cases. When we
conceived our study, we decided to include those cases, because the
focus was strictly on postoperative morbidity of ttMIE – independent
of the indications. We agree that the majority of patients undergoes
esophagectomy for esophageal carcinoma. However, with the inten-
tion to picture clinical reality as close as possible, we chose to include
benign indications as well as other malignant and semimalignant
esophageal diseases, like GIST. One could assume that tubular
esophagectomy without lymphadenectomy might possibly influence
postoperative morbidity; however, due to their very small number in
our cohort, these cases only have an insignificant impact on results,
and therefore, are not expected to bias the message of the paper.
Your second question referred to the high rate of McKeown
procedures in our study cohort. Unfortunately, we have no data on the
decision process for McKeown and Ivor Lewis esophagectomy,
because this was not included in our database. However, there
was no distinct pattern of preferred techniques among the centers:
some performed both types of procedure, while others almost
exclusively performed either IL or MK. However, some of the larger
centers started with MK – probably to avoid an intrathoracic
anastomosis during the initial experience – and later moved on to IL.
This also relates to your third question about the potentially
higher leakage rate of thoracoscopic esophago-gastrostomy. The
scientific evidence comparing minimally invasive with open intra-
thoracic anastomosis is still very limited; thus, we cannot generally
exclude a higher risk for anastomotic fistula in the thoracoscopic
approach. Your last question referred to conversion rates. Again, this
was not included in our database. We agree that this may be
considered as a potential limitation of our study; however, when
we planned our study design, we did not consider this a problem
because the focus was strictly on postoperative morbidity of the
benchmark procedure: a completed total minimally invasive
transthoracic esophagectomy.
Christophe Mariette (Lille, France):
Congratulations for the very interesting presentation. I have
some concerns regarding the paper and the methodology used. The
first point is that you mentioned that the ideal circumstance for
studying esophagectomy on a benchmarking point of view is trans-
thoracic esophagectomy. You cite also low postoperative morbidity
rate, surgical expert teams, and minimally invasive esophectomy.
However, I’m not in agreement with the last issue, since no guide-
lines recommending minimally invasive esophagectomy has been
published to date. So, do you think it can be considered as a standard?
The second point is about the McKeown esophagectomy
procedure with first a thoracotomy and then a gastric pull up through
the abdominal and cervical compartments. You mentioned that it’s an
ideal procedure, whereas some others have shown that placing the
anastomotis in the neck is not the optimal way, leading to an
increased rate of postoperative mortality, especially for low or middle
third esophageal adenocarcinomas. Please comment. Third, some
continents are missing here. Normally, for benchmarking you have to
have various continents represented. Here you have European centers
and only 1 American center. Please comment. Finally, the dimen-
sions usually to be considered in such business process are quality,
time and cost. In the paper, nothing about the costs is reported.
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Response from Christian A. Gutschow (Zurich,
Switzerland):
Prof. Mariette, thank you for your remarks. I am aware that
ttMIE is not recommended as a standard procedure in the actual
guidelines. However, morbidity after ttMIE has been shown to be
lower compared with the conventional approach in a number of meta-
analyses and oncologic outcome was equivalent in the randomized
TIME trial. I fully agree that the evidence published so far does not
allow for definite conclusions, but we are convinced that ttMIE, if
performed by experts, has the potential for a benchmark procedure.
Concerning your second question about potential superiority of
the McKeown approach, I assume that there must have been some
misunderstanding. In our benchmark patients, there were no statisti-
cally significant differences for most parameters analyzed except for a
statistically higher number of resected lymph nodes in the McKeown
group. However, this difference was not clinically relevant.
Your third question relates to the contributing centers origi-
nating from 2 continents only. I fully agree: unfortunately, we were
not successful in recruiting Asian, African, or Australian centers.
This may be due to the fact that ttMIE is a relatively young procedure
and many surgeons are still in their ‘‘experimental’’ phase. There-
fore, it will be necessary to update this analysis relatively soon, and
we are confident to be able to convince more centers from overseas
to participate.
Your last question related to cost-effectiveness of ttMIE.
When we conceived our study, we did not include this because
the focus was clearly on morbidity of ttMIE. Also, we expected
difficulties to analyze cost-effectiveness in a multinational study.
Olivier Farges (Clichy, France):
Thank you very much for your presentation. Two short ques-
tions: First, have you observed differences in outcome between the
13 centers? If not, does it suggest that your proposed benchmark
values cannot discriminate quality of care between high-volume
centers? Second, is an expert center only defined by its
annual caseload?
Response from Christian A. Gutschow (Zurich,
Switzerland):
Prof. Farges, thank you for your questions. Indeed, we did not
find significant differences among the contributing centers for
standard morbidity parameters in the benchmark cohort. In our
opinion, this mirrors the high level of care in the centers that
contributed to this study. Referring to your second question, I truly
think that a high case load – it was at least 20 esophagectomies per
year in our study – is necessary to achieve a certain level of expertise
and quality. This has been shown in a number of studies: center and
surgeon volumes correlate well with outcome in esophageal surgery.
In our study, besides case load, hospital inclusion criteria were also
the availability of a prospective database and a special commitment
to esophageal surgery as documented by recent publications.
Editorial Comment by Christophe Mariette (Lille,
France):
Defining a point of reference – the benchmark – against
which the results of others can be compared with define a best
possible outcome under ideal circumstances is emerging and of
interest in the surgical field. Definition of the ideal circumstances
in the present paper is debatable since totally minimally invasive
esophagectomy has not been demonstrated as a standard approach
and patients included represent a highly selected group operated on
in high volume centers, including their learning curve. Reporting on
long-term outcomes and cost-effectiveness would offer strength to
the concept.
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